Can-Fite BioPharma Ltd. (CANF) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Comparison side by side

We are contrasting Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Can-Fite BioPharma Ltd. 3.62M 7.31 4.84M -0.26 0.00
Ionis Pharmaceuticals Inc. 599.67M 17.68 276.87M 0.51 137.95

In table 1 we can see Can-Fite BioPharma Ltd. and Ionis Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS)?s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Can-Fite BioPharma Ltd. -133.70% 0% 0%
Ionis Pharmaceuticals Inc. 46.17% -31.1% -8.7%

Analyst Recommendations

Can-Fite BioPharma Ltd. and Ionis Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Can-Fite BioPharma Ltd. 0 0 0 0.00
Ionis Pharmaceuticals Inc. 0 0 1 3.00

Meanwhile, Ionis Pharmaceuticals Inc.?s average price target is $82, while its potential upside is 7.04%.

Institutional & Insider Ownership

Institutional investors owned 23.43% of Can-Fite BioPharma Ltd. shares and 89.1% of Ionis Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 0.2% of Ionis Pharmaceuticals Inc.?s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Can-Fite BioPharma Ltd. 8.77% 3.33% -12.06% -0.8% -29.14% -1.59%
Ionis Pharmaceuticals Inc. 14.3% 21.53% 21.62% 52.61% 33.45% 30.39%

For the past year Can-Fite BioPharma Ltd. had bearish trend while Ionis Pharmaceuticals Inc. had bullish trend.

Summary

On 10 of the 12 factors Ionis Pharmaceuticals Inc. beats Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.